Molecular domain structures of ABL1 family kinases.23 Specificity of selected ABL tyrosine kinase inhibitors is shown. The kinase selectivity profiles for imatinib, nilotinib, and dasatinib were generated on the basis of binding of cellular kinases to inhibitors immobilized on solid support matrices; ponatinib sensitive kinases were identified by in vitro kinase assays; shown are targets with half maximal inhibitory concentration values less than 20 nM. Abbreviations: AVR2B, activin receptor type 2B; BLK, B lymphoid tyrosine kinase, CSF1R, macrophage colony stimulating factor 1 receptor; EGFR, epidermal growth factor receptor; EPHRs, ephrin receptors; FGFR, fibroblast growth factor receptor; FRK, fyn-related kinase; GAK, cyclin-G-associated kinase; GCK, glucokinase; ILK, integrin-linked protein kinase; LIMK, Lim domain kinase; NLK, nemo-like kinase; NQO2, NAD(p)H dehydrogenase, quinone 2; PDGFR, platelet-derived growth factor receptor; PTK, protein tyrosine kinase; RIPK2, receptor-interacting serine/threonine-protein kinase 2; SIK, salt-inducible kinase; SLK, STE20-like serine/threonine-protein kinase; TAOK3, TAO kinase 3; TESK2, dual specificity testis-specific protein kinase 2; VEGFR, vascular endothelial growth factor receptor. (Used with permission.)